MedPage Today on MSN2d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's DrugTreatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
GlobalData on MSN6d
UK’s pricing watchdog rejects Alzheimer treatments for the second timeThe UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Zacks Investment Research on MSN2d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback